Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-03
2006-10-03
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S254010, C514S321000, C514S326000, C544S368000, C544S372000, C544S398000, C544S399000, C544S400000, C544S360000, C544S364000, C544S121000, C544S129000, C544S374000, C546S198000, C546S208000, C546S236000, C546S237000, C546S248000, C546S214000, C546S193000, C546S194000
Reexamination Certificate
active
07115610
ABSTRACT:
Disclosed are novel substituted heterocyclic derivatives having the structure of Formula I:The compounds are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, diabetes, and myocardial infarction.
REFERENCES:
patent: 4558129 (1985-12-01), Kluge et al.
patent: 4567264 (1986-01-01), Kluge et al.
patent: 4766125 (1988-08-01), Van Daele et al.
patent: 5472707 (1995-12-01), Samuels et al.
patent: 5506229 (1996-04-01), Dow et al.
patent: 5906988 (1999-05-01), Dow
patent: 6451798 (2002-09-01), Varkhedkar et al.
patent: 6552023 (2003-04-01), Zablocki et al.
patent: 6573264 (2003-06-01), Zablocki et al.
patent: 6677336 (2004-01-01), Zablocki et al.
patent: 6677343 (2004-01-01), Blackburn et al.
patent: 6849632 (2005-02-01), Zablocki et al.
patent: 2003/0176447 (2003-09-01), Ibrahim et al.
patent: 2003/0181352 (2003-09-01), Ibrahim et al.
patent: 048 932 (1992-05-01), None
patent: 2034 305 (1980-06-01), None
patent: WO 01/62744 (2001-08-01), None
patent: WO 02/064576 (2002-08-01), None
patent: WO 03/008411 (2003-01-01), None
Archibald, J.L. et al., “Antihypertensive Ureidopiperidines”, J.Med. Chem. 23(8):857-861, (1980).
McCormick, et al. “Ranolazine: A Novel Metabolic Modulator for the Treatment of Angina”, Gen Pharmac., vol. 30, No. 5, pp. 639-645, (1998).
Suzuki T et al: “Structure-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer.”, Journal of Chemistry, vol. 40, No. 13, 1997, pp. 2047-2052, XP000924067, the whole document, particularly p. 2049, table 2, compound 5.
Zacharowski K et al: “Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat.” European Journal of Pharmacology, vol. 418, No. 1-2, Apr. 20, 2001, pp. 105-110, XP002215620, the whole document.
Lopaschuk G D: “Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism”, The American Journal of Cardiology, vol. 82, No. 5A, Sep. 3, 1997, pp. 14K-17K, XP002215621, the whole document.
Elzein Elfatih
Ibrahim Prabha
Palle Venkata
Rehder Kenneth
Zablocki Jeffrey
Bernhardt Emily
CV Therapeutics Inc.
CV Therapeutics, Inc.
Hartrum J. Elin
Lewis Brian
LandOfFree
Substituted heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3642971